New Drugs Developed to Fight Against Antimicrobial Resistance


A new and first of its kind database has been launched listing compounds that could be used to develop new antibiotics in a bid to tackle the global issue of antimicrobial resistance (AMR). The study results are published in the Journal of Antimicrobial Chemotherapy

It comes after the World Health Organization in 2009 declared AMR one of the biggest threats to mankind and, if not addressed, by 2050 it could kill millions of people—more than from cancer or road traffic accidents.

The free, open-access, searchable database called AntibioticDB brings together antibacterial compound discoveries that were once-promising leads from the past 40 years which have, for various reasons, been dropped or stalled, and may otherwise be overlooked by drug-development companies.

Lead author Professor Laura Piddock said: "Antimicrobial resistance (AMR) threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses and fungi.

"New resistance mechanisms are emerging and spreading globally, threatening our ability to treat common infectious diseases, resulting in prolonged illness, disability, and death.

Pre-clinical and clinical development

"One answer to the crisis seems simple: to generate new antibiotics. However, it can take up to 15 years and cost up to $5 billion from the discovery of a compound to progress through pre-clinical and clinical development before a medicine can be licensed and then marketed.

"There is no doubt that the antibiotic pipeline needs revitalization; however, the answer may be not only the development of new drugs but also re-investigating compounds previously discontinued.

"For this reason, we have developed and populated an easy to use the database of antibiotics that can be accessed for free by anybody; we hope this will help both academia and commercial companies with their drug-discovery efforts."

The database includes links to data on the discovery, research and clinical trials, compounds awaiting approval and discontinued compounds, providing a platform for future research, antibiotic discovery and development in the hope this will inspire the lifesaving drugs of tomorrow.

One of the authors of the study, Professor Tony Maxwell of the John Innes Centre, adds: "We wanted to establish the current status of the drug-discovery pipeline in antibiotic development—particularly to look at compounds that might have been dropped in the past to see if they could be resuscitated.

The research team used a range of sources to identify compounds of interest, including key opinion leaders in the pharmaceutical industry and leading agencies in this research area.

Information on each compound or drug was obtained using online searches, literature archives and interviewing prominent experts. Further information such as reasons for the lack of development is also included.

Different dosages

The study highlights examples from the past where drugs have been dropped on safety grounds, only to be re-introduced successfully years later after new research showed them to be safe at different dosages.

While other pay-per-view resources exist for researchers, AntibioticDB is the first free database designed to appeal to small and medium-sized enterprises or academia.

Rebecca Lo said: "We hope this might lead to more joined-up drug discovery in this area, encouraging companies, academics, and governments to work together. "It would be fantastic if the database could stimulate new initiatives to investigate forgotten antibiotics."